Growth Hormone Secretagogues & GHRH Analogs: Research Guide
This guide provides a comprehensive scientific overview of growth hormone secretagogues (GHS) and growth hormone-releasing hormone (GHRH) analogs used in research. These compounds target the somatotropic axis — the physiological system regulating growth hormone (GH) secretion, insulin-like growth factor 1 (IGF-1) production, and downstream anabolic signaling.
Table of Contents
- The Growth Hormone Axis
- GHRH Analogs: CJC-1295 & Tesamorelin
- GH Secretagogues: Ipamorelin
- IGF-1 LR3: Downstream Signaling
- Combination Research Protocols
- Compound Comparison Table
See also: Mitochondrial Peptides in Research: A Complete Scientific Guide, Peptide Blends & Stacking in Research: A Complete Scientific Guide, Custom Peptide Synthesis: A Complete Scientific Guide.
References & Further Reading
The Growth Hormone Axis
The somatotropic axis represents a complex endocrine feedback system involving the hypothalamus, pituitary gland, liver, and peripheral tissues. Growth hormone secretion is primarily regulated by two hypothalamic peptides with opposing actions:
- GHRH (Growth Hormone-Releasing Hormone): Stimulates GH synthesis and pulsatile release from somatotroph cells in the anterior pituitary
- Somatostatin: Inhibits GH secretion through a tonic inhibitory mechanism
Additionally, ghrelin — a hormone produced primarily in the stomach — acts on the growth hormone secretagogue receptor (GHS-R) to stimulate GH release through a distinct pathway from GHRH. This dual regulatory system provides multiple targets for research peptide intervention.
GH exerts many of its effects indirectly through stimulation of hepatic IGF-1 production. IGF-1 mediates many anabolic and metabolic actions of GH, including protein synthesis, cell proliferation, and tissue growth.
GHRH Analogs
CJC-1295
CJC-1295 is a synthetic analog of human GHRH designed with enhanced pharmacokinetic properties. It incorporates modifications that increase its resistance to enzymatic degradation and extend its duration of action. Two variants exist — with and without Drug Affinity Complex (DAC) — which significantly differ in half-life and release profile. Full guide: CJC-1295 Explained: GHRH Analog, DAC vs No-DAC.
CJC-1295 with DAC binds to endogenous albumin, creating a circulating depot that slowly releases the active peptide, resulting in sustained GHRH receptor activation. The non-DAC variant has a shorter half-life and produces a more pulsatile GH release profile, more closely mimicking endogenous secretion patterns.
Tesamorelin
Tesamorelin is a synthetic GHRH analog containing a hexenoyl modification to the N-terminal tyrosine residue, which improves metabolic stability. It has been investigated primarily in the context of visceral adipose tissue research and GH-deficiency models. Full analysis: Tesamorelin: GHRH Analog, Fat Loss Research.
GH Secretagogues
Ipamorelin
Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin receptor (GHS-R1a) agonist. Unlike earlier GH secretagogues, ipamorelin is highly selective for GH release with minimal effects on cortisol, prolactin, or aldosterone — making it a preferred tool for studying isolated GH axis activation. Detailed guide: Ipamorelin Explained: Selective GH Secretagogue.
IGF-1 LR3: Downstream Signaling
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is an analog of human IGF-1 with an extended half-life. By acting directly at the IGF-1 receptor, it bypasses GH-dependent IGF-1 production and provides a tool for studying downstream anabolic signaling independent of upstream GH regulation. Comprehensive review: IGF-1 LR3 Explained: Growth Signaling.
Combination Research Protocols
In research contexts, GHRH analogs and GH secretagogues are sometimes studied in combination:
- CJC-1295 + Ipamorelin: Targets both GHRH and GHS pathways simultaneously
- GHRH analog + IGF-1 LR3: Investigates both upstream regulation and downstream effector mechanisms
- Tesamorelin + metabolic compounds: Body composition and metabolism research
Compound Comparison Table
| Compound | Class | Receptor Target | Half-Life | Key Feature |
|---|---|---|---|---|
| CJC-1295 (DAC) | GHRH analog | GHRH-R | Extended (days) | Albumin binding depot |
| CJC-1295 (No DAC) | GHRH analog | GHRH-R | Short (hours) | Pulsatile profile |
| Tesamorelin | GHRH analog | GHRH-R | Short | Hexenoyl modification |
| Ipamorelin | GH secretagogue | GHS-R1a | Short | Selective GH release |
| IGF-1 LR3 | IGF-1 analog | IGF-1R | Extended | Bypasses GH regulation |
Further Reading
- CJC-1295 Explained: GHRH Analog
- Tesamorelin: GHRH Analog & Fat Loss
- Ipamorelin Explained: Selective GH Secretagogue
- IGF-1 LR3 Explained: Growth Signaling
Disclaimer: This guide is intended for scientific research and educational reference purposes only. All compounds discussed are intended for laboratory research use only.
